Nomogram for Individualized Prediction and Prognostic Factors for Survival in Patients with Primary Spinal Chordoma: A Population-Based Longitudinal Cohort Study
Overview
Authors
Affiliations
Background: Chordoma is a type of rare bone tumor and is a relatively slow-growing, low-grade malignancy that is locally invasive and aggressive. The nomogram is widely used in the field of cancer because it can provide a clear picture for clinicians to predict the survival rate, which can lead more accurate decisions in clinical treatment.
Methods: Overall, 875 patients with a primary spinal chordoma were identified and collected from the Surveillance, Epidemiology, and End Results registry databases (1973-2015). The nomogram was established based on 425 patients with complete data. The predictive accuracy and discriminative ability of the nomogram were determined by the concordance index (C-index) and calibration curve.
Results: The statistical nomogram was built on 10 independent prognostic factors: age, sex, race, disease stage, surgery, year of diagnosis, marital status, primary site, radiation, and tumor size, with C-indices of 0.76. The calibration curve to determine the probability of survival showed good agreement between the predictions by the nomogram and actual observation. Tumor diameter >10 cm (hazard ratio [HR] 2.95, 95% confidence interval [CI] 1.77-4.90, P < 0.001), regional invasive (HR 1.71, 95% CI 1.16-2.53, P < 0.01), and distant metastasis (HR 3.44, 95% CI 1.98-5.96, P< 0.001) were independent risk factors for poor survival. Undergoing subtotal resection or gross total resection (HR 0.37, 95% CI 0.25-0.56, P < 0.001; HR 0.26, 95% CI 0.17-0.41, respectively) and a primary site located in the sacrum/pelvis (HR 0.51, 95% CI 0.34-0.78, P < 0.01) were prognostic factors for better survival.
Conclusions: The nomogram provided more accurate prognostic predictions for patients with spinal chordoma. Moreover, our study suggests that tumor diameter >5 cm, distant metastasis, and not performing resection are major risk factors that can dramatically decrease the survival time of patients with spinal chordoma.
Population-based survival analysis of primary spinal chordoma in the US from 2000 to 2020.
Agner K, Larkins M J Neurooncol. 2024; 170(2):397-405.
PMID: 39331221 PMC: 11538232. DOI: 10.1007/s11060-024-04807-y.
Tang W, Li R, Lai X, Yu X, He R Heliyon. 2024; 10(17):e37013.
PMID: 39286090 PMC: 11402751. DOI: 10.1016/j.heliyon.2024.e37013.
Battistin U, Nguyen R, Ghaith A, El-Hajj V, Soltan F, Ghaith S J Neurooncol. 2024; 169(2):359-368.
PMID: 39102119 DOI: 10.1007/s11060-024-04745-9.
Goumenos S, Kakouratos G, Trikoupis I, Gavriil P, Gerasimidis P, Soultanis K Cancers (Basel). 2024; 16(5).
PMID: 38473334 PMC: 10930783. DOI: 10.3390/cancers16050973.
Pham J, Shaaya E, Rhee B, Kimata A, Ozcan E, Pham K Front Oncol. 2024; 13:1327330.
PMID: 38352297 PMC: 10862492. DOI: 10.3389/fonc.2023.1327330.